** Shares of Chinese biotechnology firm Laekna slump 14.9% to HK$13.38, on course for the biggest one-day pct drop since April 16
** Stock third-biggest pct loser in Hang Seng Composite Index , which slips 0.2%
** Laekna plans to sell 17.64 mln new shares to raise HK$235.6 mln ($30.27 mln) for accelerating research and development of obesity drug LAE102 and other drug assets
** New shares will be issued at HK$13.36 each, a 15.01% discount to Wednesday's close of HK$15.72 per share
** Stock soared 48% on Wednesday after it entered into agreement with Eli Lilly to develop an experimental obesity drug LAE102 to help patients lose weight while preserving muscle
** Hang Seng Commerce & Industry Index climbs 0.1%, healthcare index adds 0.03%, while Hang Seng Index
slips 0.1%
** Laekna shares down 29.4% YTD ($1 = 7.7828 Hong Kong dollars)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
